In this video, Bob Langreth and I debate which is showing more signs of life, Bristol, with its comeback, or Novo Nordisk, which has become a big pharmaceutical company by focusing on diabetes with a big focus on insulin.
For one thing, the drug seemed to decrease patient's lung function--apparently the result of the way the insulin, a big, complicated protein, was delivered into the lungs.
Part of the issue is that the benefit of taking insulin is so big--preventing blindness and organ damage--that even a small long-term cancer risk might be acceptable.